Korean J Schizophr Res Search


Korean Journal of Schizophrenia Research 2008;11(2):97-106.
Ziprasidone의 임상적 사용 지침
Seung Hwan Lee, MD1, Ung Gu Gang, MD2, Jae Jin Kim, MD3, Chan Hyung Kim, MD3, Jung Seo Yi, MD4, Yeon Ho Joo, MD5, Kyung Sue Hong, MD6 and Jun Soo Kwon, MD2
Ziprasidone is an atypical antipsychotic agent having an antagonistic effect on dopaminergic receptor (D2) and type2 serotonergic receptor (5HT2). It has shown excellent efficacy against positive and negative symptoms of schizophrenia and better side effect profiles compared to other atypical antipsychotics (i.e., lower metabolic syndrome rate, lower extrapyramidal symptoms rate, and less somnolence, etc.). This article presents clinical guidelines for using ziprasidone focusing on four subtopics, i.e., ‘initiation and titration’, ‘drug switch’, ‘drug compliance’, and ‘identifying the high priority patient’. The recommendations are based on clinical literatures, expert consensus suggestions developed in Canada and Australia, Zeldox Consumer Medical Information, and clinical experiences of the authors. Much more controlled and naturalistic clinical studies on ziprasidone use should be accumulated to develop more evidence-based and comprehensive version of clinical guidelines. (Korean J Schizophr Res 2008;11: 97-106)
Key Words: Ziprasidone,Clinical guideline,Dosage,Switching,Adverse effect
Share :
Facebook Twitter Linked In Google+ Line it
METRICS Graph View
  • 769 View
  • 3 Download
Related articles in Korean J Schizophr Res


Browse all articles >

Editorial Office
15 Teheran-ro 82-gil, Gangnam-gu, Seoul 06178, Korea
Tel: +82-2-552-6677    Fax: +82-31-554-2599    E-mail: thanato96@naver.com                

Copyright © 2024 by Korean Society for Schizophrenia Research.

Developed in M2PI

Close layer
prev next